title: Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.
abstract: The impact of intraocular involvement (IOL) in primary CNS lymphoma (PCNSL) has not been sufficiently evaluated. Here, we present the analysis of IOL in the only completed randomized phase III trial in PCNSL. The G-PCNSL-SG1 study evaluated the role of whole-brain radiotherapy in primary therapy of PCNSL. Data of the 526 eligible study patients were checked, and clinical characteristics, therapy, and outcome of patients with IOL diagnosed at study inclusion were analyzed. Ophthalmologic examination at study inclusion was performed in 297 patients (56.5 %) of whom IOL was diagnosed in 19 (6.4 %). Clinical characteristics did not significantly differ between patients with IOL (IOL+) and those without (IOL-). The median progression-free survival (PFS) in the IOL+ group was 3.5 months (95 % CI 0.0-7.07) as compared to 8.3 months (95 % CI 4.78-11.78) in the IOL- group (P = 0.004), the median overall survival (OS) was 13.2 months (95 % CI 0.86-25.62) and 20.5 months (95 % CI 15.56-25.5), respectively (P = 0.155). In multivariate analysis, a significantly inferior PFS and OS for IOL+ patients were found. IOL at diagnosis of PCNSL was an independent negative prognostic indicator for PFS and OS in this analysis.
authors.affiliation: Department of Hematology & Oncology, Campus Benjamin Franklin, Charite, Hindenburgdamm 30, 12200, Berlin, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Kreher
authors.forename: Felicitas
authors.initials: F
authors.lastname: Strehlow
authors.forename: Peter
authors.initials: P
authors.lastname: Martus
authors.forename: Patrick
authors.initials: P
authors.lastname: Roth
authors.forename: Bernd
authors.initials: B
authors.lastname: Hertenstein
authors.forename: Alexander
authors.initials: A
authors.lastname: Röth
authors.forename: Tobias
authors.initials: T
authors.lastname: Birnbaum
authors.forename: Frank
authors.initials: F
authors.lastname: Griesinger
authors.forename: Michael
authors.initials: M
authors.lastname: Rauch
authors.forename: Lothar
authors.initials: L
authors.lastname: Kanz
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korfel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000150:complications / Q000401:mortality* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D004305:Dose-Response Relationship, Drug; D005128:Eye Diseases / Q000175:diagnosis* / Q000209:etiology*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000401:mortality* / Q000532:radiotherapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D008727:Methotrexate